Ascorbic Acid to Prevent Postreperfusion Syndrome in Liver Transplantation

The goal of this clinical trial is to test the efficacy of intravenous ascorbic acid in preventing the postreperfusion syndrome in liver transplantation. The main questions it aims to answer are:Can intravenous ascorbic acid prevent postreperfusion syndrome in liver transplantation ?Can ascorbic acid decrease the incidence of liver graft dysfunction after liver transplantation?Can ascorbic acid decreased the incidence of postoperative complications after liver transplantation ?Participants will receive 1.5 g of intravenous ascorbic acid diluted in 100 ml of saline or 100 ml of saline alone, during the anhepatic phase of liver transplantation before reperfusion of the new graft.Researchers will compared the incidence of postreperfusion syndrome in both groups.

Inclusion Criteria:Patients undergoing liver transplantationExclusion Criteria:PregnancyAllergy to ascorbic acidNephrolithiasisGlucose-6-phosphate dehydrogenase (G6PD) deficiencyHyperoxaluriaHyperuricemiaHaemochromatosisSickle cell anemiaSerum Creatinine > 1.2 mg/dl in women and 1.3 mg/dl in menSplit liver graftAcute liver failureLiving donor liver transplantationControlled donor asystoliaTreatment with: indinavir, Vitamin B12, Cyclosporine, iron, deferoxamine, disulfiram